Clinical trials: Phosphorus Metabolism Disorders, active
Peri Implant Mucositis, Peri Implant Bone Loss
Local and Systemic Inflammatory Bone Alterations Related to Dental Implant Survival.
Introduction: Dental implants offer a durable, aesthetic, and functional option for tooth replacement. However, they are not immune to failure.
- Conditions
- Peri Implant Mucositis, Peri Implant Bone Loss, Peri Implantitis, Calcium Deficiency
- Trial name
- NCT07766707
- Where
- Spain
- Volunteers
- 192 people
- Sponsor
- University of Barcelona
X Linked Hypophosphatemia
Burden of Disease and Functional Impairment in XLH
Observational study comprising prospective follow up as well as retrospective chart review in order to evaluate the longitudinal course of the disease in XLH patients with a specific focus on functional impairment, physical…
- Trial name
- IdeFIX (NCT04946409)
- Testing
- no intervention
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Wuerzburg University Hospital
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate.
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Trial name
- RESPOND-2 (NCT06933472)
- Testing
- AP301, AP301 Low Dose
- Where
- 42 sites in United States, China
- Volunteers
- 264 people
- Sponsor
- Alebund Pharmaceuticals
Mechanical Ventilation, Weaning Failure
Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning
Hypophosphatemia is a common phenomenon in the ICU, and several retrospective studies have shown that hypophosphatemia is associated with prolonged mechanical ventilation in ICU patients.
- Conditions
- Mechanical Ventilation, Weaning Failure, Hypophosphatemia
- Trial name
- NCT06754670
- Testing
- Sodium Glycerophosphate 216 MG/ML
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College
Kidney Failure, Chronic, Hyperphosphatemia
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested.
- Trial name
- PHOSPHATE (NCT03573089)
- Testing
- Liberal phosphate target, Intensive phosphate target
- Where
- 126 sites in Australia, Brazil and 7 more
- Volunteers
- 3,600 people
- Sponsor
- The University of Queensland
X-linked Hypophosphatemia
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
- Trial name
- NCT06525636
- Testing
- KK8123
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 39 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Refeeding Syndrome, Critical Illness
Respiratory Quotient and Phosphate Changes During Early Critical Illness
Critically ill patients often experience major changes in metabolism during the first days of intensive care. When nutrition is started or increased after a period of reduced intake, some patients may develop refeeding syndrome…
- Conditions
- Refeeding Syndrome, Critical Illness, Metabolic Changes During Critical Illness
- Trial name
- IC-REFEED (NCT07800143)
- Testing
- Nutritional Exposure During Early Critical Illness
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
X-linked Hypophosphatemia (XLH)
Effective Dosing of Burosumab in XLH
X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells.
- Trial name
- NCT07183579
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Nottingham
Hypophosphatemia, Kidney Transplantation
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
- Trial name
- NCT06824454
- Testing
- Dipyridamole 75 MG
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Osteogenesis Imperfecta, Rare Bone Disorders
Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis
MOSAIC aims to determine whether oro-dental morphological anomalies, particularly palatal morphology, associated with rare bone and cartilage diseases can be precisely characterized using 3D digital models analysed through…
- Conditions
- Osteogenesis Imperfecta, Rare Bone Disorders, Hypophosphatemia, X-Linked
- Trial name
- MOSAIC (NCT07666269)
- Testing
- intra-oral 3D optical impression
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Hyperphosphatemia, Maintenance Hemodialysis
Tenapanor in Maintenance Hemodialysis Patients
The investigators hypothesize that Tenapanor can improve serum phosphorus control and regulate intestinal metabolism in maintenance hemodialysis patients without increasing the risk of severe gastrointestinal adverse events.
- Trial name
- NCT07882017
- Testing
- Tenapanor
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Huashan Hospital
Kidney Stones, Calcium Oxalate Kidney Stones
Phosphate & Kidney Stones
Kidney stones are common and often come back. One reason may be that some people with calcium stones have low phosphate levels in the blood and lose too much phosphate through the kidneys.
- Conditions
- Kidney Stones, Calcium Oxalate Kidney Stones, Hypophosphatemia
- Trial name
- NCT07903961
- Testing
- Neutral Phosphate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Chicago
X-linked Hypophosphatemia, Hypophosphatemic Rickets
X-linked Hypophosphatemia Disease Monitoring Program
The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
- Trial name
- NCT03651505
- Testing
- No intervention
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 782 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Phosphate Diabetes, X-linked Hypophosphatemia
Phosphorus-31 Spectroscopy in Phosphate Diabetes
Phosphate diabetes is defined by urinary phosphate wasting due to impaired tubular reabsorption. It can be classified based on either a genetic or acquired origin.
- Trial name
- Phos-ATP (NCT06921720)
- Testing
- intra-muscular ATP values in phosphate diabetes, intra-muscular phosphate values in phosphate diabetes
- Where
- 2 sites in France
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
X-Linked Hypophosphatemia
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 10 years, the study intends to collect data that allow achievement of the following objectives: 1.
- Trial name
- SUNFLOWER (NCT03745521)
- Testing
- no intervention
- Where
- Japan
- Volunteers
- 226 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Hyperphosphatemia
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
- Trial name
- NCT06206135
- Testing
- the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- LG Chem
Pulmonary Arterial Hypertension
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form.
- Trial name
- NCT07737522
- Testing
- GLP-1 agonist
- Volunteers
- 32 people
- Sponsor
- Imperial College London
X-Linked Hypophosphatemia
Registry for Patients With X-Linked Hypophosphatemia
This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH).
- Trial name
- NCT03193476
- Where
- 118 sites in Belgium, Bulgaria and 18 more
- Volunteers
- 1,489 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd